PRESS RELEASES |
2018
June 2018
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
April 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
February 2018
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
January 2018
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
April 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
February 2018
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
January 2018
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer